BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BioCentury | Apr 22, 2017
Finance

Sweden heating up

Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
BC Week In Review | May 19, 2014
Company News

Lumena Pharmaceuticals, Shire deal

Shire will acquire Lumena for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed milestone payments tied to clinical trials of LUM001...
BC Extra | May 13, 2014
Company News

Shire to acquire Lumena

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Lumena Pharmaceuticals Inc. (San Diego, Calif.) for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BC Extra | Apr 4, 2014
Financial News

Lumena files for IPO

Lumena Pharmaceuticals Inc. (San Diego, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Citigroup; Cowen; and Leerink. The offering comes on the heels of a $45 million series...
BioCentury | Mar 17, 2014
Finance

Building a liver powerhouse

Building a liver powerhouse Lumena Pharmaceuticals Inc. will use last week's $45 million series B round to support expanded Phase II testing of LUM001 in cholestatic liver disease and a planned Phase II trial for...
BC Extra | Mar 12, 2014
Financial News

Lumena secures $45 million in series B

Lumena Pharmaceuticals Inc. (San Diego, Calif.) secured $45 million in a series B round led by new investor New Enterprise Associates. New investors Adage Capital Management and RA Capital Management also participated, along with existing...
BC Week In Review | Jan 27, 2014
Clinical News

LUM001 regulatory update

The European Commission granted Orphan Drug designation to LUM001 from Lumena to treat Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). The inhibitor of ileal Na+ bile...
Items per page:
1 - 10 of 1143
BioCentury | Dec 27, 2019
Product Development

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BioCentury | Apr 22, 2017
Finance

Sweden heating up

Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences...
BioCentury | Aug 22, 2016
Finance

Northern Lights 2.0

A sea change is taking place in the Scandinavian biotech ecosystem, as an uptick in acquisitions and international investor syndicates shows science coming out of the region's academic institutes is increasingly able to find a...
BC Week In Review | May 19, 2014
Company News

Lumena Pharmaceuticals, Shire deal

Shire will acquire Lumena for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed milestone payments tied to clinical trials of LUM001...
BC Extra | May 13, 2014
Company News

Shire to acquire Lumena

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Lumena Pharmaceuticals Inc. (San Diego, Calif.) for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed...
BioCentury | May 12, 2014
Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
BC Extra | Apr 4, 2014
Financial News

Lumena files for IPO

Lumena Pharmaceuticals Inc. (San Diego, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Citigroup; Cowen; and Leerink. The offering comes on the heels of a $45 million series...
BioCentury | Mar 17, 2014
Finance

Building a liver powerhouse

Building a liver powerhouse Lumena Pharmaceuticals Inc. will use last week's $45 million series B round to support expanded Phase II testing of LUM001 in cholestatic liver disease and a planned Phase II trial for...
BC Extra | Mar 12, 2014
Financial News

Lumena secures $45 million in series B

Lumena Pharmaceuticals Inc. (San Diego, Calif.) secured $45 million in a series B round led by new investor New Enterprise Associates. New investors Adage Capital Management and RA Capital Management also participated, along with existing...
BC Week In Review | Jan 27, 2014
Clinical News

LUM001 regulatory update

The European Commission granted Orphan Drug designation to LUM001 from Lumena to treat Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). The inhibitor of ileal Na+ bile...
Items per page:
1 - 10 of 1143